

# Pneumonia: diagnosis and management (update) Committee meeting 3

**Date:** 13/02/2024

**Location:** Virtual

Minutes: Final

Committee members present:		
Tessa Lewis (Chair)	Present for notes 1 – 10	
Sumiah Al-Azeib	Present for notes 1 – 10	
Tom Bewick	Present for notes 1 – 10	
Srini Bandi	Present for notes 1 – 10	
Dan Furmedge	Present for notes 1 – 5, part of 6 & 7 -10	
Alastair Hay	Present for notes 1 – 10	
Jennifer Head	Present for notes 2 – 10	
Philip Howard	Present for notes 1 – 10	
Marisa Lanzman	Present for notes 1 – 10	
Paddy McMaster	Present for notes 1 – 10	
Mitul Patel	Present for notes 1 – 10	
Carole Pitkeathley	Present for notes 1 – 8, part of 9	
Kathryn Thomas	Present for notes 1 – 10	
Avril Tucker	Present for notes 2 – 10	
Martin Williams	Present for notes 1 – 10	
Caroline Ward	Present for notes 1 – 10	
Dan Wootton	Present for notes 2, 4 -10	

In attendance:				
Steph Armstrong	Senior Health Economist	Present for notes 1 – 10		
Chris Carmona	Technical Adviser	Present for notes 1 – 10		
Jackie Durkin	Administrator	Present for notes 1 only		
Chris Harris	Project Manager, NICE	Present for notes 1 – 10		
Joanna Perkin	Senior Medical Editor, NICE	Present for notes 1 – 10		
Paul Levay	Information Specialist	Present for notes 1 – 10		
Eric Slade	Health Economics Adviser	Present for notes 6		

Hannah Stockton	Technical Analyst	Present for notes 1 – 10
Michellie Young	Technical Analyst	Present for notes 1 – 10

Apologies:	
Simran Chawla	Public Involvement Adviser, NICE
Dan Horner	Committee member
Joy Okafor	Committee member
Alan Thomas	Committee member
Nick Staples	Guideline Commissioning Manager
Rachel Walsh	Technical Analyst, NICE

#### 1. Welcome and introductions

The Chair welcomed Committee members and attendees to the third meeting on Pneumonia: diagnosis and management (update). The Committee members and attendees introduced themselves.

The Chair informed the Committee that apologies had been received. These are noted above. The minutes of the previous meeting were confirmed as a true and accurate record.

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was diagnosis and management of pneumonia.

The Chair asked everyone to verbally declare any interests. The following new interests were declared:

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Tom Bewick	Consultant	National Respiratory	Non-	Non specific
		financial, Professional	Declare and participate	
		and personal interest	Rationale: Not specific to the scope of the guideline	
Philip	Pharmacist	Co-Investigator on	Non-	Non-specific
Howard		NIHR funded PEACH	financial,	
		study: Procalcitonin	Professional	Declare and
		evaluation of antibiotic	and	participate
		use in COVID-19	personal	

	hospitalised patients	interest	Rationale:
			COVID-19 is
			excluded from
			the scope for the
			update.

The Chair and a senior member of the Developer's team noted that an interest previously declared by Dan Wooton would pose a conflict for the recommendation drafting of review question 3.1. As such Dan will not be present or participate in the recommendation drafting for this item. It was noted no other previously declared interests would prevent attendees from fully participating in the meeting.

2 & 3. Review question 3.1: What is the clinical and cost effectiveness of care outside of the acute hospital setting (for example using intermediate care, hospital at home, virtual wards) for people with intermediate risk community-acquired pneumonia diagnosed in primary care/hospital?

#### Presentation of clinical evidence and committee discussion

The Chair introduced Hannah Stockton, Technical Analyst who presented the committee with the clinical evidence relating to review question 3.1. The committee discussed the evidence presented and drafted recommendations accordingly.

4 & 5. Review question 6.1: In people with community- or hospital-acquired pneumonia what is the clinical effectiveness and cost effectiveness of corticosteroid treatment in addition to antibiotic treatment compared with antibiotic treatment alone? (adults only)

#### Presentation of clinical evidence and committee discussion

The Chair introduced Michellie Young, Technical Analyst who presented the committee with the clinical evidence relating to review question 6.1 for adults. The committee discussed the evidence presented and drafted recommendations accordingly.

#### 6. Health economic modelling – final prioritisation

The Chair introduced Steph Armstrong, Senior Technical Economist who took the committee through a short presentation on the prioritisation for health economic modelling. The committee discussed several options and reached agreement. Several committee members volunteered to be part of a health economic subgroup.

### 7 & 8. Pneumonia guideline discussion

The Chair introduced Chris Carmona, Technical Advisor who took the committee through a short presentation on the guideline update, asking the committee for input and clarity on the points raised. The Chair thanked Chris for his presentation and

the committee for their contributions.

### 9. Review Protocols

The Chair introduced Hannah Stockton, Technical Analyst who presented the committee with draft review protocols. The committee discussed these and asked questions, for the developer team to refine them.

## 10. AOB and next steps

There was no other business. Chris Harris, Project Manager, outlined the next steps for the committee and gave a brief reminder on NICE's declarations of interest policy before the Chair thanked those present and closed the meeting.

Date of next meeting: 28/03/2024

Location of next meeting: Virtual